Trial reportJAMA network open2026
Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.
Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Oxycodone and hydrocodone are the most frequently prescribed opioids for postoperative joint arthroplasty pain, yet comparative effectiveness data remain limited. Objective: To compare postoperative pain outcomes and opioid consumption for hydrocodone vs oxycodone among patients undergoing elective joint arthroplasty. Design, Setting, and Participants: This cohort study was a preplanned secondary analysis of a randomized clinical trial conducted among cytochrome P450 2D6 (CYP2D6) normal metabolizers (NMs) who underwent elective joint arthroplasty in 5 US surgery clinical sites from March 2021 to September 2023 and received hydrocodone or oxycodone postoperatively. Follow-up concluded in March 2024. Data analysis was conducted from October 2024 to December 2025. Exposure: Postoperative analgesia with hydrocodone or oxycodone within a multimodal pain management approach (opioids and nonopioids). Main Outcomes and Measures: Coprimary outcomes were composite pain score at postoperative day 10 (sum of current, worst, and mean pain over 7 days; range 3-15) and cumulative morphine milligram equivalents (MMEs) over 10 days. Secondary outcomes included mobility scores at day 10 and Patient-Reported Outcomes Measurement Information System anxiety and depression scores at day 30. Multivariable regressions were adjusted for demographic and clinical covariates. Results: Among 663 participants (mean [SD] age, 66 [10.6] years; 384 [57.9%] female), 217 received oxycodone and 446 received hydrocodone. Hydrocodone was associated with significantly lower composite pain scores compared with oxycodone (mean [SD], 9.0 [2.0] vs 9.3 [2.2]; adjusted P = .001) and significantly lower cumulative MME (mean [SD], 93.5 [159.3] vs 154.5 [121.6]; adjusted P < .001). Secondary outcomes did not differ between groups (mobility score: mean [SD], 26.3 [10.4] vs 30.9 [14.7]; P = .29; anxiety score: mean [SD], 45.4 [8.3] vs 45.5 [8.7]; P = .31; depression score: mean [SD], 43.8 [7.8] vs 44.0 [7.9]; P = .97). Findings were consistent in sensitivity analyses, restricting to opioid and acetaminophen combinations, restricting to sites prescribing both opioids, and in subgroups of knee arthroplasty, but not consistent in hip arthroplasty. Conclusions and Relevance: In this cohort study of CYP2D6 NMs undergoing joint arthroplasty, within multimodal analgesia, hydrocodone provided comparable pain control to oxycodone with significantly lower opioid exposure, supporting its use as a viable and possibly preferable analgesic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.